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Aims: Serine protease inhibitor B1 (SerpinB1) is a neutrophil elastase inhibitor that
has been proved to be associated with type 2 diabetes mellitus and pancreatic β-cell
proliferation. In this study, we investigated 2 SERPINB1 SNPs, rs114597282 and
rs15286, regarding their association with diabetes risk and various anthropometric and
biochemical parameters in Egyptian type 2 diabetic patients.
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Materials and Methods: A total of 160 subjects (62 control and 98 type 2 diabetic
patients) participated in this study. Various anthropometric and biochemical parameters
were assessed. Genotyping assay for the two SNPs was done using TaqMan genotyping
assays. The association of rs15286 variants with risk of diabetes, various biochemical
parameters, and glycemic control in diabetic patients was assessed.
Results: All genotyped subjects were found to be homozygous TT for SERPINB1
rs114597282. All genotype variants of SERPINB1 rs15286 were found in our Egyptian
subjects with A being the minor allele. The SNP rs15286 was not found to be associated
with risk of diabetes. The AA genotype was found to be associated with lower fasting
plasma glucose, lower HbA1c %, and better β-cell function and glycemic control in
diabetic patients. The G allele was associated with poor glycemic control.
Conclusions: The genotypes AA, AG, and GG of SERPINB1 gene SNP rs15286 are
all represented in the studied sample; however, it is not associated with risk of diabetes.
Genotype AA of SNP rs15286 is associated with better glycemic control and better β-cell
function in diabetic patients, while the G allele potentially represents the “risk allele” of
poor glycemic control.
Keywords: serpinB1, type 2 diabetes mellitus, β-cell dysfunction, insulin resistance, hepatokines, gene
polymorphism

INTRODUCTION
Diabetes mellitus (DM) is a complex multifaceted metabolic disorder. Unfortunately, its global
prevalence is growing at an alarming rate especially in middle- and low-income countries (1).
The number of people suffering DM globally has risen from about 108 million in 1980 to nearly
422 million in 2014 (2), with a further expected increase to about 630 million people worldwide
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for Teaching Hospitals and Institutes (NIDE—GOTHI) under
number IDE00203, and informed consent was obtained
from every enrolled subject. The study was carried out in
accordance with the Declaration of Helsinki recommendations
and regulations (21). A total of 160 subjects were enrolled
in the study; 62 non-diabetic healthy control subjects and 98
patients with type 2 DM. The definition of a non-diabetic was
a subject who has a fasting plasma glucose (FPG) level lower
than 110 mg/dl and has no family history of type 2 DM. All the
control subjects were not receiving any dietary supplements or
medications and were not suffering any health problems. The
98 patients with type 2 DM were recruited from the outpatient
clinic of the National Institute of Diabetes and Endocrinology
(NIDE). These 98 patients were further classified into diabetics
with good glycemic control (HbA1c ≤ 7%) and diabetics with
poor glycemic control (HbA1c > 7%) as described previously
(22) for odds ratio calculations. The characteristics of all
the study subjects are summarized in Table 1. The exclusion
criteria included renal or hepatic disease, thyroid dysfunction,
acute or chronic inflammatory disease, type 1 DM, ischemic
cardiovascular disease, cancer, acute or chronic infections,
alcohol or drug abuse, and any hematological disorder. Subjects
taking hormonal therapy were also excluded.
All the study subjects underwent physical examination and
detailed history and laboratory investigations. Anthropometric
measures included waist-to-hip ratio (WHR) and body mass
index (BMI); body weight and standing height were measured in
light clothing without shoes. The BMI was calculated as weight
divided by squared height (kg/m2 ). Waist circumference was
measured to the nearest 0.1 cm at the narrowest point between
the lowest rib and the uppermost lateral border of the iliac crest,
while the hip was measured at its widest point.

by the year 2045 (1). Type 2 DM is the most common type of DM,
and genetic-predisposition accounts for nearly 60–90% of the
susceptibility to its development (3). During the natural course
of the disease, insulin resistance and β-cell loss or dysfunction
are potential drivers for the various metabolic abnormalities
associated with type 2 DM (3, 4). When the functional insulinsecreting β-cell mass is compromised, the normal physiological
glucose homeostasis is disrupted and type 2 DM manifests (5).
Accordingly, vigorous efforts have been exerted over the past
years to develop strategies which would help to compensate
and/or expand functional β-cells. Among those approaches
was the identification of factors/mediators capable of inducing
proliferation and expansion of preexisting functional β-cells (5,
6). That approach attracted much interest especially that β-cell
expansion and compensation capabilities have been reported
in various conditions associated with insulin resistance such as
obesity (7, 8) or pregnancy (9). Interestingly, in this regard, ElOuaamari and coworkers highlighted the integrative cross talk
between the liver and pancreatic β-cells via the secretion of
hepatocyte-derived factor(s) in response to insulin resistance
which induces β-cell proliferation (10).
Among these hepatocyte-derived factors, serine protease
inhibitor B1 (serpinB1; serpin family B member 1) has been
identified to play an important role in that process of βcell compensation in response to insulin resistance (11).
Interestingly, serpinB1 was also previously reported to act as
a neutrophil elastase inhibitor (12), and improving glucose
tolerance and insulin sensitivity was found to be associated
with such inhibition (13). Additionally, a recent report sheds
light on the possible association of serpinB1 with insulin
sensitivity in healthy adults (14). It is noteworthy that serpinB1
is not the only serpin which could be associated with insulin
sensitivity. Long before, the visceral adipose tissue-derived
serpin—Vaspin—was also identified as an interesting insulinsensitizing adipokine (15), with a putative interplay with other
mediators in compensatory mechanisms for insulin resistance in
type 2 DM (16).
Nevertheless, genetic variants of the SERPINB1 gene and their
possible implication into β-cell dysfunction and reduced β-cell
compensation in diabetic patients have not been investigated
(17). Just one family has been identified with a possibly damaging
SERPINB1 variant associated with diabetes (11). Thus, knowing
that genome-wide association studies have revealed several
genetic variants related to compromised β-cell function to be
associated with type 2 DM (18, 19), as well as the extra layer
of complexity in different ethnic populations (20), this inspired
us to investigate if genetic variants of SERPINB1 are associated
with diabetes risk, glycemic control, and β-cell dysfunction in
Egyptian type 2 diabetic patients. According to our knowledge,
this is the first report investigating the association of SERPINB1
genetic variants with type 2 DM.

Blood Sampling
All the blood samples were drawn after overnight fasting, and
the samples were divided into four aliquots. The first aliquot
of blood was collected on plain vacutainer tubes for serum
preparation used for the assay of the lipid profile, as well as
C-peptide levels. The second aliquot of blood was collected
on vacutainer tubes containing sodium fluoride for measuring
fasting plasma glucose (FPG). The third and fourth aliquots
of blood were collected on vacutainer tubes containing sodium
EDTA for measuring glycated hemoglobin (HbA1C %), and for
subsequent DNA extraction from whole blood. Afterward, serum
samples were divided into aliquots and stored at −80◦ C for
subsequent assays.

Laboratory Analyses
FPG and serum biochemical parameters including triglycerides
(TG), total cholesterol (TC), and high-density lipoproteincholesterol (HDL-C) were measured using Spectrum Diagnostics
kits (Egypt). Low-density lipoprotein cholesterol (LDL-C)
levels were calculated by Friedewald’s equation (23). HbA1C %
was determined using ion-exchange high-performance liquid
chromatography (HPLC) by the Bio-Rad D-10 system (Bio-Rad
Laboratories, Hercules, CA, USA).
Afterward, serum C-peptide levels were determined using
the human C-peptide ELISA kit (DRG, USA). The homeostasis

MATERIALS AND METHODS
Study Population and Anthropometric
Measurements
This study was approved by the ethical committee of the National
Institute of Diabetes and Endocrinology—General Organization
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TaqMan Universal Master Mix No UNG (Thermo Fisher
Scientific, USA). Genotyping was done using a StepOnePlus
thermal cycler (Applied Biosystems, USA). 20 ng of genomic
DNA for each sample was genotyped using 10 µL (2×) TaqMan R
Universal Master Mix, 0.5 µL (40×) TaqMan R SNP genotyping
assay, and DNAse/RNAse-Free water (Gibco, Life Technologies,
USA) to a total volume of 20 µL reaction using default
genotyping settings with appropriate negative control.

TABLE 1 | Clinical and laboratory characteristics of the studied groups.
Factor

Controls

Type 2 DM

p-value

p-value¶

N (F/M)

62 (42/20)

98 (46/52)

……

……

Age (year)

38.2 ± 1.1

49.1 ± 1.1

<0.001a

……..

…….

8.39 ± 0.74

……

…….

BMI (kg/m2 )

Diabetes duration (year)

28.8 ± 0.62

31.5 ± 0.53

0.001a

0.002

WHRc

0.92 ± 0.08

0.95 ± 0.013

0.085b

0.845

86.5 ± 1.6

209.6 ± 7.4

<0.001b

<0.001

HbA1C (%)

5.4 ± 0.07

8.4 ± 0.22

<0.001a

Statistical Analysis

<0.001

TC (mg/dl)

150.6 ± 5.0

209.0 ± 5.2

<0.001a

<0.001

88.2 ± 5.02

127.4 ± 4.4

<0.001b

<0.001

47.1 ± 0.74

44.7 ± 1.41

0.014b

0.165

TG (mg/dl)c

80.2 ± 4.8

177.9 ± 9.6

<0.001b

<0.001

LDL-C/HDL-Cc

1.96 ± 0.13

3.22 ± 0.19

<0.001b

<0.001

TC/HDL-Cc

3.3 ± 0.15

5.11 ± 0.22

<0.001a

<0.001

C-peptide (ng/ml)c

3.81 ± 0.26

0.84 ± 0.054

<0.001b

<0.001

HOMA2-β%c

213.6 ± 11.3

17.9 ± 1.2

<0.001b

<0.001

HOMA2-IRc

2.73 ± 0.19

0.94 ± 0.07

<0.001b

<0.001

…….

35/3/60

…….

…….

All results were expressed as mean ± standard error of mean
(S.E.M). The Kolmogorov–Smirnov test was done to evaluate the
distribution of various variables. The independent-sample t-test
and Mann–Whitney U-test were used appropriately according
to the data distribution for comparison between non-diabetic
control and type 2 DM groups. The genotype distribution was
validated to follow the Hardy–Weinberg equilibrium (HWE)
using an online calculator (25), and the chi-square (χ2)
test was used to compare allele frequency distributions of
various genotypes in the studied groups. Finally, binary logistic
regression analysis was used to calculate the odds ratios (ORs)
and 95% confidence intervals (CIs) to investigate the possible
association of rs15286 variants with type 2 DM or with glycemic
control status. Kruskal–Wallis or one-way ANOVA tests were
used appropriately according to the distribution of data for
comparison between the levels of various parameters in various
genotypes (3 groups) followed by Dunn’s test for Kruskal–
Wallis as multiple-comparison post hoc tests. General linear
modeling (GLM), followed by Bonferroni post hoc test for
multiple comparisons, was used to control for covariates such
as age, gender, and BMI, and p-values were calculated after
correction for these covariates. Any non-normally distributed
data was logarithmically transformed before performing GLM.
All statistical analyses were performed using Windows-based
SPSS statistical package (SPSS version 17.0, SPSS Inc, Chicago,
IL). P-values ≤ 0·05 were considered significant.

FPG (mg/dl)

c

LDL-C (mg/dl)
HDL-C (mg/dl)

c

Type of treatment
(OHA/OHA +
insulin/insulin)

Results are expressed as mean ± S.E.M. DM, diabetes mellitus; BMI, body mass
index; WHR, waist to hip ratio; FPG, fasting plasma glucose; TC, total cholesterol;
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol;
TG, triglycerides; HbA1C %, glycosylated hemoglobin; HOMA2-β%, homeostasis
model assessment-β-cell function; HOMA2-IR, homeostasis model assessment-insulin
resistance; OHA, oral hypoglycemic agent.
a Independent-sample T-test, two-tailed, p-value >0.05 non-significant. b Mann–Whitney
U test, two-tailed, p-value >0.05 non-significant. c Log transformed for performing GLM.
¶ P-value after adjustment for age, gender, and BMI by GLM. All significant p-values are
written in bold and italics.

model assessment of β-cell function (HOMA2-β%) and insulin
resistance (HOMA2-IR) was calculated from FPG (mg/dl) and
fasting C-peptide (ng/ml) levels using an online HOMA2
calculator/algorithm (24). HOMA2 models were calculated using
C-peptide to avoid interference of insulin in patients treated
by insulin. All ELISA procedures were done according to
the manufacturer’s instructions using the ChroMate microplate
reader (Awareness Technology, USA).

RESULTS
Clinical Laboratory Data of the Study
Subjects
As shown in Table 1, this study included 160 subjects; 62
subjects (42 females and 20 males) who were apparently healthy
volunteers served as the control group. The type 2 DM group
consisted of 98 patients (46 females and 52 males). The mean age
of the control group was 38.2 ± 1.1 years, while that of the type
2 DM group was 49.1 ± 1.1 years. The duration of diabetes was
8.39 ± 0.74 years. The body mass index was significantly elevated
in the type 2 DM group as compared to the control group.
However, the waist–hip ratio (WHR) was almost equal in both
groups. In addition, FPG, HbA1C %, and lipid profile including
TG, TC, LDL-C, and even LDL-C/HDL-C and TC/HDL-C were
all significantly elevated in type 2 DM as compared to the
control group.
As for β-cell function indices, C-peptide was significantly
decreased in type 2 DM patients as compared to control subjects
(0.84 ± 0.054 ng/ml and 3.81 ± 0.26 ng/ml, respectively, p <

DNA Extraction and Genotyping Assay
The extraction of DNA from 150 µL whole blood (collected
on EDTA anticoagulant) was done using the commercially
available Quick DNA Miniprep Kit (Zymo Research, USA)
according to the manufacturer’s instructions, then the
extracted DNA was quantified using a Quawell micro-volume
spectrophotometer (USA).
Genotyping was done for 2 SERPINB1 polymorphism,
namely, SERPINB1 rs114597282, which is a missense mutation
with a C/T substitution (previously determined as a possibly
damaging variant for SERPINB1 gene) (11). The other SNP was
SERPINB1 rs15286, which is a transition A/G SNP (in the 3′ UTR
region of SERPINB1). Genotyping was done using TaqMan R
SNP Genotyping assays with the following IDs: C_151309206_10
for rs114597282 and C____950920_1 for rs15286 using the
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TABLE 2 | Association of SERPINB1 rs15286 variants with risk of type 2 DM.
Serpin B1 rs15286 genotypes

Controls n = 62

Diabetic n = 98

n (%)

n (%)

AA

3 (4.8%)

6 (6.1%)

AG

22 (35.5%)

26 (26.5%)

GG

37 (59.7%)

66 (67.4%)

25 (40.3%) vs. 37 (59.7%)

32 (33.6%) vs. 66 (66.4%)

AG/AA vs. GG
AG/GG vs. AA

Total

59 (95.2%) vs. 3 (4.8%)

92 (93.9%) vs. 6 (6.1%)

62 (100%)

χ2

p-value

OR (95% CI)

1.473

0.479

0.707 (0.392–1.274)

0.249

0.655 (0.322–1.332)

0.242¶

0.974
0.118

0.324
0.731

p-value

0.718 (0.371–1.388)

0.324

0.741 (0.338–1.623)

0.454¶

0.780 (0.188–3.238)

0.732

0.799 (0.14–4.54)

0.800¶

98 (100%)

A χ2 test was done for various genotypes, A allele and G allele, and diabetes status. The odds ratio (OR) was calculated using binary logistic regression using diabetes status as the
dependent variable and genotype as the covariate, in addition to adjustment for age, gender and BMI as additional covariates.
¶ Adjusted for the effect of covariates: age, gender, and BMI.

shown in Table 3, all parameters failed to reach a significant
difference among AA, AG, and GG genotypes in the control
group. On the other hand, in the diabetic group, these
genotypes showed a significant difference for FPG, HbA1C %, and
HOMA2-β% (p-values = 0.008, 0.006, and 0.004, respectively).
In order to gain further insight into the difference of these
parameters’ levels among various genotypes of diabetic patients,
we compared the levels among these parameters pair-wise.
Figure 1A showed that genotype AA is significantly associated
with lower FPG as compared to both AG and GG genotypes (FPG
AA: 141 ± 7.5 mg%, AG: 224.8 ± 13.8 mg%, and GG: 209.8 ±
9.1 mg%, p-value = 0.008). Similarly, HbA1C % was significantly
lower in the AA genotype than both AG and GG genotypes
but failed to reach a significant increase in GG (HbA1C %: AA:
6.6 ± 0.3%, AG: 8.97 ± 0.3%, and GG: 8.4 ± 0.3%, p-value =
0.006) as shown in Figure 1B. Interestingly, HOMA2-β% showed
significant elevation in the AA genotype as compared to both AG
and GG genotypes (HOMA2-β% AA: 32.8 ± 4.7%, AG: 14.4 ±
1.7, and GG: 18 ± 1.5, p-value = 0.004) as shown in Figure 1C.
It is noteworthy that even after adjustment for age, gender,
and BMI, genotype AA subjects remained relatively significantly
different from the AG genotype regarding FPG, HbA1C %, and
HOMA2-β% levels (adjusted p-values were 0.014, 0.057, and
0.003, respectively) and also from the GG genotype (adjusted
p-values were 0.035, 0.23, and 0.011, respectively).
Moreover, we studied the association of the various genotypes
with the glycemic control status in the genotyped diabetic
patients. We found that there is a significant difference in the
distribution of the various genotypes (AA, AG, and GG) between
the good and the poor glycemic control of diabetic patients (pvalue = 0.002). On the other hand, there was no significant
association between good glycemic control and the AA or AG
genotype, i.e., the A allele (OR = 0.627; CI = 0.233–1.691; pvalue = 0.357). Interestingly, there was a significant association
between the AA genotype and prediction of good glycemic
control (OR = 10.324, CI = 1.088–97.965; p-value = 0.042).
Actually, these last OR and CI are the same for the AG or GG
genotype, i.e., the G allele and the poor glycemic control in
diabetic patients. All ORs and CIs are shown before and after
adjustment for age, gender, and BMI in Table 4.

0.001). Moreover, HOMA2-β% was also severely diminished in
type 2 diabetic patients as compared to the control group (17.9 ±
1.2% and 213.6 ± 11.3%, respectively, p < 0.001) (Table 1).

Association of SERPINB1 rs15286 Variants
With Type 2 DM Risk
As for the SERPINB1 SNP rs114597282, 100% of the subjects
either control or type 2 DM were found to have a homozygous
TT genotype, which unfortunately hindered further processing
or studying of any association of such SNP.
The distribution and the alleles’ frequencies of the rs15286
SNP of SERPINB1 are shown in Table 2. The observed
distribution frequency of various alleles followed the Hardy–
Weinberg equilibrium. The AA genotype represents the minor
genotype in both control and type 2 DM groups with 4.8 and
6.1%, respectively, with a total of 5.625% of all subjects. On the
other hand, GG was the major genotype in the genotyped subjects
(60% in control and 67% in type 2 DM patients) with a total of
64.375% of all subjects. As for the AG genotype, it represented
35.5% in the control group and 26% in the diabetic group with
an overall 30% of the subjects. In addition, the A allele represents
the minor allele with 40% in control and 33.6% in the diabetic
subjects, with a total of 35.625% of the studied subjects. The
2 groups did not differ significantly regarding the distribution
of various genotypes (p-value = 0.479) and the frequency of A
allele (p-value = 0.324) or G allele (p-value = 0.731). Moreover,
the various genotypes, A allele or G allele, were not found to be
associated with the risk of DM (OR = 0.655, CI = 0.322–1.332,
p-value = 0.242; OR = 0.741, CI = 0.338–1.623, p-value = 0.454;
OR = 0.799, CI = 0.14–4.54, p-value = 0.800, respectively). All
ORs (95% CI) were adjusted for age, gender, and BM.

Anthropometric and Biochemical
Parameters’ Levels in Various Genotypes
of SERPINB1 rs15286 SNP
In order to study the levels of various parameters in the
genotyped samples, we compared the levels of various
anthropometric and biochemical parameters among the
genotype variants in both control and type 2 DM groups. As
Frontiers in Endocrinology | www.frontiersin.org
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TABLE 3 | Association of SERPINB1 rs15286 variants with various anthropometric and clinical characteristics of the studied subjects.
Parameter

SerpinB1 rs15286 genotypes
Control
AA

N (F/M)

AG

Type 2 DM
GG

p-value

p-value¶

AA

AG

GG

p-value

p-value¶

3 (3/0)

22 (15/7)

37 (24/13)

—–

—-

6 (4/2)

26 (13/13)

66 (29/37)

—-

—-

Age (year)

29.7 ± 3.8

40.4 ± 2.1

37.6 ± 1.3

0.116a

—–

54.7 ± 4.5

47.2 ± 2

49.3 ± 1.3

0.271a

—-

BMI (kg/m2 )

30.1 ± 5.2

28.3 ± 1.2

29.1 ± 0.7

0.778a

—–

31.7 ± 1.6

31.8 ± 0.9

31.4 ± 0.7

0.934a

—-

WHRc

0.89 ± 0.02

0.92 ± 0.01

0.93 ± 0.01

0.469b

0.772

0.97 ± 0.02

0.95 ± 0.03

0.95 ± 0.02

0.522b

0.670

FPG (mg/dl)c

81 ± 7.2

90.8 ± 2.3

84.5 ± 2.2

0.11b

0.17

141 ± 7.5

224.8 ± 13.8

209.8 ± 9.1

0.008b, **

0.018 *

HbA1C (%)c

5.38 ± 0.02

5.6 ± 0.1

5.3 ± 0.1

0.083b

0.109

6.6 ± 0.3

8.97 ± 0.3

8.4 ± 0.3

0.006b, **

0.055

TG (mg/dl)c

78.7 ± 24

78.9 ± 8.9

81.1 ± 6

0.733b

0.872

248.3 ± 44.5

172.9 ± 16.9

173.5 ± 11.8

0.258b

0.439

TC (mg/dl)

162.7 ± 18.8

155.1 ± 5.1

147 ± 7.7

0.65a

0.529

212.7 ± 21.3

212.7 ± 9.1

207.3 ± 6.6

0.889a

0.892

LDL-C (mg/dl)

104.7 ± 16.3

92.3 ± 5.9

84.5 ± 7.5

0.587a

0.484

115.7 ± 12.8

128.3 ± 8.6

128.1 ± 5.5

0.797a

0.633

HDL-C (mg/dl)c

42 ± 4.6

47.1 ± 1.2

47.5 ± 0.9

0.385b

0.128

47 ± 3.8

45.8 ± 2.7

44.1 ± 1.8

0.601b

0.750

LDL-C/HDL-Cc

2.5 ± 0.4

2 ± 0.17

1.9 ± 0.2

0.164b

0.147

2.5 ± 0.29

3.2 ± 0.37

3.3 ± 0.24

0.561b

0.716

3.9 ± 0.5

3.4 ± 0.19

3.2 ± 0.2

0.22b

TC/HDL-Cc
C-peptide (ng/ml)
HOMA2-β%c
HOMA2-IR

c

c

0.208

4.6 ± 0.37

5.1 ± 0.4

5.2 ± 0.27

0.881b

0.878

b

0.386

0.98 ± 0.2

0.75 ± 0.04

0.87 ± 0.08

0.2b

0.247

0.413

32.8 ± 4.7

14.4 ± 1.7

18 ± 1.5

0.004b, **

0.004 **

0.30

0.83 ± 0.16

0.86 ± 0.07

0.98 ± 0.1

0.781b

0.963

4.4 ± 0.8

4.1 ± 0.4

3.6 ± 0.36

0.239

280 ± 75.6

202.2 ± 15.8

215 ± 15.5

0.571b

2.5 ± 0.26

b

3 ± 0.49

3 ± 0.29

0.127

Results are expressed as mean ± S.E.M. p-values are shown for ANOVA or Kruskal–Wallis test, before and also after adjustment for age, gender, and BMI by GLM. DM, diabetes
mellitus; BMI, body mass index; WHR, waist to hip ratio; FPG, fasting plasma glucose; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein
cholesterol; TG, triglycerides; HbA1C %, glycosylated hemoglobin; HOMA2-β%, homeostasis model assessment-β cell function; HOMA2-IR, insulin resistance.
a ANOVA, two-tailed, p-value >0.05 non-significant. b Kruskal–Wallis, two-tailed, p-value >0.05 non-significant. c Log transformed for performing GLM. ¶ P-value after adjustment for age,
gender and BMI by GLM. *Significant at p < 0.05 level. **Significant at p < 0.01 level. All significant p-values are written in bold and italics.

FIGURE 1 | Association of SERPINB1 rs15286 variants with various parameters in type 2 DM. (A) FPG, (B) HbA1C %, and (C) HOMA2-β%. The top and bottom
whiskers represent the minimum and maximum values, while the band inside the box represents the median. *Significantly different from genotype AA at p < 0.05.
**Significantly different from genotype AA at p < 0.01, assessed by the Kruskal–Wallis test followed by Dunn’s post hoc test.

DISCUSSION

AG, and GG, were expressed in both control and diabetic subjects
with AA being the minor genotype, while GG was the major
genotype in both studied groups. However, we failed to find an
association with the distribution of these genotypes with the risk
of diabetes. Interestingly, we found that diabetic subjects having a
rs15286 AA genotype showed lower levels of FPG and HbA1C %,
as well as higher HOMA2-β% compared to other genotypes.
Moreover, there exists a significant association of genotype AA
with the prediction of good glycemic control in diabetic patients,
an association not found with the A allele alone. Meanwhile, our
results showed a positive association between the G allele and
the prediction of poor glycemic control. This indicates that type

In this study, we assessed two SERPINB1 gene SNPs in control
and type 2 DM patients and investigated their association with
the risk of diabetes and other anthropometric and biochemical
parameters. The first SNP was SERPINB1 rs114597282, which
is a missense mutation with a C/T substitution. The other one
was SERPINB1 rs15286 which is a transition A/G SNP in the
3′ UTR region of the SERPINB1 gene. For SNP rs114597282,
all our subjects, either control or diabetic patients, were of TT
genotype, which did not allow any further analyses for this SNP.
As for the other SNP rs15286, various genotypes, namely, AA,
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TABLE 4 | Association of SERPINB1 rs15286 variants with the glycemic control status of type 2 DM.
Serpin B1 rs15286
genotypes

Good glycemic control
(HbA1C ≤ 7%) n = 31

Poor glycemic control
(HbA1C >7%) n = 67

n (%)

n (%)

χ2

p-value

OR (95% CI)

p-value

0.002**
0.006¶, **

AA

5 (16.1%)

1 (1.5%)

AG
GG

3 (9.7%)
23 (74.2%)

23(34.3%)
43 (64.2%)

12.586

0.002**

0.188 (0.064–0.551)
0.212 (0.071–0.635)

8 (25.8%) vs. 23 (74.2%)

24 (35.8%) vs. 43 (64.2%)

0.967

0.326

0.623 (0.242–1.606)

0.328

0.627 (0.233–1.691)

0.357¶

12.692 (1.414–113.917)
10.324 (1.088–97.965)

0.023 *
0.042¶, *

AG/AA vs. GG
AA vs. AG/GG

Total

5 (16.1%) vs. 26 (83.9%)

1 (1.5%) vs. 66 (98.5%)

31 (100%)

67 (100%)

7.899

0.005*

A χ2 test was done for various genotypes, A allele and G allele, and glycemic control status of diabetic patients. The odds ratio (OR) was calculated using binary logistic regression
using glycemic control status as the dependent variable and genotype as the covariate, in addition to adjustment for age, gender, and BMI as additional covariates.
¶ Adjusted for the effect of covariates: age, gender, and BMI.
*Significant at p < 0.05. **Significant at p < 0.01. All significant p-values are written in bold and italics.

major one with 64.4% of total subjects. These results approached
genotype frequencies from the 1,000 Genomes database, where
the overall distribution of the genotypes in all populations were
AA 7% (was 5.6% in our study), AG 37% (was 30% in our study),
and GG 56% (was 64.4% in our study). The A allele represents
the minor allele with 36.25% in the studied groups as compared
to the minor allele frequency (MAF) of 25% and the G allele
of 75% from the 1,000 Genomes phase 3 database. This is the
first report about the frequency of this genotype in the Egyptian
population which approaches the distribution of several other
populations. This SNP requires further association studies on
other populations and in other diseases.
In fact, the distribution and frequency of these genotypes
failed to be associated with the risk of diabetes. However, we
found that the AA genotype was significantly associated with
lower FPG and HbA1C % in diabetic patients. This finding implies
that although this SNP genotype is not predictive of developing
diabetes, individuals with AA genotypes are potentially less
hyperglycemic and exhibit easier control on their diabetes, This
was further confirmed with the positive association of the AA
genotype and the good glycemic control in diabetic patients,
while carriers of one G allele are under risk of poor glycemic
control. We also observed that the presence of one A allele
is not enough to reach a significant association with such
good glycemic control. These findings may prove important
in several ways. First, further studies should be conducted
to explore if the patients with the AA genotype are less
prone or, alternatively, patients with the G allele are more
prone to diabetic complications which are mostly caused by
hyperglycemia and associated glucotoxicity (28). Second, the
AA patients may require lower doses of oral hypoglycemic or
even insulin treatment to avoid possible hypoglycemia associated
with excessive insulin or OHA dosing. Third, although more
population-based studies are required, for SERPINB1 SNP
rs15286 so far, we can consider the G allele as the “bad allele” or
the “risk allele.” Diabetic patients who are carriers of the G allele
are under risk of poor glycemic control and should be closely

2 diabetic patients’ carriers of the AA genotype may potentially
have better control over their blood glucose levels and better βcell function than other genotypes of this SERPINB1 SNP. On the
other hand, those who are carriers of a G allele are at risk of poor
glycemic control.
SerpinB1, also known as a monocyte neutrophil elastase
inhibitor, is a protease inhibitor that regulates several
inflammatory responses (26). Lately, serpinB1 has been
associated with insulin signaling in 2 ways. First, neutrophil
elastase was found to be associated with hepatic and adipose
tissue insulin resistance and its deletion may improve insulin
sensitivity (13). Second, EL-Ouaamari and coworkers could
prove serpinB1 as a novel liver-derived secretory protein that
promotes proliferation of human and mouse β-cells (11). Since
then, a couple of reports tried to study the possible association
of serpinB1 with insulin sensitivity or with type 2 DM (14, 27).
However, still the genetic variants of the SERPINB1 gene and
their association with diabetes have not been studied.
Accordingly, we decided to study two SERPINB1 SNPs and
their association with various anthropometric and biochemical
parameters in type 2 DM in comparison to control subjects. One
of these SNPs was introduced by EL Ouaamari et al., namely,
rs114597282, as a possibly damaging variant (11). However, we
failed to find the various variants in our genotyped subjects
as 100% of our subjects were homozygous TT. This comes in
accordance with a previous reported frequency of 1.7% among
African Americans and 0.01% among Europeans according to the
1,000 Genomes database. This may well explain that we failed to
get any other variants from our 160 total subjects. Accordingly,
further investigations are warranted on a larger sample size and
in different populations to study this SNP in association with
diabetes or even other diseases.
As for the other SNP rs15286, to our knowledge, this is the
first report concerning this SNP for SERPINB1 especially in
DM. Our genotyped samples showed the 3 genotypes with AA
being the minor genotype representing 5.6% of total subjects,
AG representing 30% of the total subjects, and GG being the
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of serpinB1, which may explain the better glycemic control
associated with various genotypes. Finally, further studies are
warranted to further elucidate the clinical impact of rs15286
variants on diabetic patients’ treatment regimen in Egyptian as
well as other populations.

monitored for their hyperglycemia. However, clinical trials are
warranted to test these hypotheses.
Another interesting finding in this study is the higher
HOMA2-β% associated with the AA genotypes in comparison
to other genotypes. SerpinB1 has been portrayed as a β-cellprotective hepatokine. Whether the AA genotype may provide
enhanced/better protection than other genotypes is a question
that warrants further investigations especially in prediabetic
patients. It is noteworthy that this is the first study that explores
the association of a SERPINB1 SNP variant with β-cell function
in diabetic patients.
Nevertheless, this study faced several limitations that we
have been aware of. First, further studies with larger samples
representable of the different ethnic populations are warranted.
Second, our failure to find various variants of the SNP
rs114597282 constrained our capability to further study this SNP.
In fact, although this study was limited by its relatively small
sample size, our results demonstrate the interplay of SERPINB1
SNP rs15826 with glycemic control in diabetic patients and
shed light on the possible implication of SERPINB1 gene
polymorphism in diabetes pathogenesis, as well as the risk for
developing diabetic complications.
In conclusion, to the best of our knowledge, this is the first
report to show that the SERPINB1 gene has the SNP rs15286
variant of all genotypes expressed in the Egyptian population,
with the A allele as the minor allele of about 35% of the
population. However, these genotypes are not associated with
risk to diabetes. The AA genotype of this SNP is associated with
an overall better glycemic control and better β-cell function in
diabetic patients. The G allele can be considered as the “risk allele”
for poor glycemic control in diabetic patients. Conclusively,
SERPINB1 SNP rs15826 can potentially predict glycemic control
in diabetic patients and can enhance better treatment options
for these patients based on their genotypes. In addition, this
study opens the door for further studies to investigate the
possible association between other SERPINB1 gene variants
and susceptibility for diabetes and/or diabetic complications in
different ethnic populations. Furthermore, further research is
required to study the effect of these SNPs on the serum levels
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